The lawsuit claims that Embecta leadership provided overly optimistic projections, specifically describing its pen needle business as "incredibly resolute" only weeks before the company missed market expectations and slashed its 2026 fiscal outlook. Plaintiffs argue that the company either knew or recklessly disregarded that its guidance was unattainable, leading to financial losses for shareholders when the reality of the firm's fiscal health surfaced.

Investors wishing to serve as lead plaintiff in the case must file a motion with the Court no later than August 17, 2026. While the lawsuit is underway, no class has been certified yet. Shareholders may choose to retain their own counsel, remain absent class members, or join the ongoing action without incurring out-of-pocket costs through the firm's contingency fee arrangement. Interested parties can contact Phillip Kim at the Rosen Law Firm for further details on the proceedings.